Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 74019P207 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Weinstein Benjamin 13G/A Amendment 1 | 4.0% |
8/24/2026
Event 8/21/2026
|
|
|
Empery Asset Management, LP
13G/A
Amendment 1
|
4.99% |
7/29/2026
Event 6/30/2026
|
|
| Empery Asset Management, LP | 4.99% | ||
| Ryan M. Lane | 4.99% | ||
|
Lynx1 Capital Management LP
13G
|
5.4% |
7/20/2026
Event 7/13/2026
|
|
| Lynx1 Capital Management LP | 5.4% | ||
| Weston Nichols | 5.4% | ||
|
Empery Asset Management, LP
13G/A
Amendment 1
|
7.6% |
4/15/2026
Event 3/31/2026
|
|
| Empery Asset Management, LP | 7.6% | ||
| Ryan M. Lane | 7.6% | ||
|
Tang Capital Management LLC
13G/A
Amendment 3
|
0% |
2/17/2026
Event 12/31/2025
|
|
| Tang Capital Management, LLC | 0% | ||
| Kevin Tang | 0% | ||
| Tang Capital Partners, LP | 0% | ||
| Tang Capital Partners International, LP | 0% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 2
|
4.1% |
2/17/2026
Event 12/31/2025
|
|
| Lynx1 Capital Management LP | 4.1% | ||
| Weston Nichols | 4.1% | ||
|
Bleichroeder LP
13G/A
Amendment 1
|
8.2% |
2/13/2026
Event 12/31/2025
|
|
| Bleichroeder LP | 8.2% | ||
| Bleichroeder Holdings LLC | 8.2% | ||
| Andrew Gundlach | 8.2% | ||
|
Octagon Capital Advisors LP
13G
|
10.0% |
2/10/2026
Event 12/31/2025
|
|
| Octagon Capital Advisors LP | 10.0% | ||
| Octagon Investments Master Fund LP | 10.0% | ||
| Ting Jia | 10.0% | ||
|
Aberdeen Group plc
13G
|
8.9% |
1/27/2026
Event 12/31/2025
|
|
| Aberdeen Group plc | 8.9% | ||
| abrdn Inc. | 8.9% | ||
|
Empery Asset Management, LP
13G
|
10.0% |
1/22/2026
Event 12/31/2025
|
|
| Empery Asset Management, LP | 10.0% | ||
| Ryan M. Lane | 10.0% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 1
|
8.8% |
11/14/2025
Event 9/30/2025
|
|
| LYNX1 Capital Management LP | 8.8% | ||
| Weston Nichols | 8.8% | ||
|
Bleichroeder LP
13G
|
9.7% |
8/14/2025
Event 6/30/2025
|
|
| Bleichroeder LP | 9.7% | ||
| Bleichroeder Holdings LLC | 9.7% | ||
| Andrew Gundlach | 9.7% | ||
|
Readout Capital, LP
13G/A
Amendment 1
|
9.4% |
8/14/2025
Event 6/30/2025
|
|
| Readout Capital, LP | 9.3% | ||
| Readout Capital GP, LLC | 9.3% | ||
| ROC Holdings SPV II, LP | 7.6% | ||
| Readout Holdings GP, LLC | 7.6% | ||
| Matthew Smith | 9.4% | ||
|
Aquilo Capital Management, LLC
13G/A
Amendment 2
|
0% |
8/6/2025
Event 6/30/2025
|
|
| Aquilo Capital, L.P. | 0% | ||
| Aquilo Capital Management, LLC | 0% | ||
| Marc Schneidman | 0% | ||
|
Novartis Pharma AG
13G/A
Amendment 2
|
3.7% |
8/6/2025
Event 6/30/2025
|
|
| Novartis Pharma AG | 3.7% | ||
| Novartis AG | 3.7% | ||
|
Tang Capital Management LLC
13G/A
Amendment 2
|
6.4% |
5/15/2025
Event 3/31/2025
|
|
| Tang Capital Management, LLC | 6.4% | ||
| Kevin Tang | 6.4% | ||
| Tang Capital Partners, LP | 3.6% | ||
| Tang Capital Partners International, LP | 2.8% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
| Highbridge Capital Management, LLC 13G/A Amendment 1 | 3.7% |
4/25/2025
Event 3/31/2025
|
|
|
Readout Capital, LP
13G
|
8.9% |
3/26/2025
Event 3/19/2025
|
|
| Readout Capital, LP | 8.8% | ||
| Readout Capital GP, LLC | 8.8% | ||
| ROC Holdings SPV II, LP | 6.9% | ||
| Readout Holdings GP, LLC | 6.9% | ||
| Matthew Smith | 8.9% | ||
| Weinstein Benjamin 13G | 5.2% |
3/18/2025
Event 3/18/2025
|
|
|
Aquilo Capital Management, LLC
13G/A
Amendment 1
|
9.9% |
2/14/2025
Event 12/31/2024
|
|
| Aquilo Capital, L.P. | 6.6% | ||
| Aquilo Capital Management, LLC | 9.9% | ||
| Marc Schneidman | 9.9% | ||
| Janus Henderson Group PLC 13G/A Amendment 2 | 0% |
2/14/2025
Event 12/31/2024
|
|
|
Lynx1 Capital Management LP
13G
|
10.0% |
2/14/2025
Event 12/31/2024
|
|
| Lynx1 Capital Management LP | 10.0% | ||
| Weston Nichols | 10.0% | ||
|
Novartis Pharma AG
13G/A
Amendment 1
|
5.4% |
2/12/2025
Event 12/31/2024
|
|
| Novartis Pharma AG | 5.4% | ||
| Novartis AG | 5.4% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 278 | $1.74 k |
| 2026 Q2 | 98 | 17.7 M | $139 M |
| 2026 Q1 | 79 | 16.2 M | $88.1 M |
| 2025 Q4 | 70 | 15.1 M | $62.8 M |
| 2025 Q3 | 57 | 4.65 M | $25.7 M |
| 2025 Q2 | 54 | 4.48 M | $18.8 M |
| 2025 Q1 | 49 | 3.79 M | $18.1 M |
| 2024 Q4 | 56 | 3.88 M | $14.7 M |
| 2024 Q3 | 53 | 3.32 M | $29.8 M |
| 2024 Q2 | 50 | 3.17 M | $30.9 M |
| 2024 Q1 | 47 | 3.20 M | $43.3 M |